Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense® E3 Smart Transmitter provides on-body vibe alerts even when the connection between the mobile device and the smart transmitter is lost (as long as your smart transmitter battery is not depleted)
Depending on your specific insurance plan, there could be differences in cost. We are happy to help you navigate getting more information about your insurance coverage. Just fill out the Pre-Qualification form, and we will be happy to contact you.
The simple answer is no. While you may optionally calibrate the Eversense E3 System more frequently, (daily calibrations entries must be spaced at least one hour apart), this will not impact the accuracy of the system.
After the 24-hour warm up period, the Eversense E3 CGM needs calibration primarily once a day. Calibrating the sensor ensures the highest accuracy throughout your daily activities.
Note: The Use by date is not an expiration date. A sensor may be inserted and a smart transmitter may be linked for the first time, up to the Use by date
Go to About > My Account to see the email address that was used to log into the mobile app.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1